Drug intelligence / Profile preview

SB02

Development stage: Preclinical
Lead developer: SynCore Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

SB02 is a small molecule anti-cancer drug candidate being developed by SynCore Biotechnology (an affiliate of the Sinphar Group) in collaboration with the National Health Research Institute (NHRI) of Taiwan. It is characterized as an anti-angiogenesis agent, designed to inhibit the formation of new blood vessels within tumors, thereby suppressing tumor growth and metastasis. SB02 was in-licensed from NHRI and is part of a series of oncology compounds that includes SB01. As of current pipeline reports, SB02 is in the IND-enabling phase of development for the treatment of various cancers.

Targets

PDGFR (PDGFR family)VEGFR (VEGFR family)FGFR (FGFR family)

Beyond the preview

Go deeper on SB02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB02.

Explore the full profile